Press releases

28 November - 2024

Toleranzia AB appoints SKMG as new Certified Adviser

Toleranzia AB (publ) has entered into an agreement with Svensk Kapitalmarknadsgranskning AB (“SKMG”) regarding the service...

25 November - 2024

Toleranzia AB publishes the Nomination Committee

Toleranzia AB (publ) publishes the Nomination Committee’s composition for the Annual General Meeting in 2025. The...

22 October - 2024

Toleranzia receives approximately SEK 37 million through the warrants of series TO4 which were exercised to approximately 85 percent

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA,...

21 October - 2024

Toleranzia AB: Interim report third quarter 2024

Three months, July 1 – September 30 Operating profit/loss amounted to KSEK -2 809 (-1 099)....

17 October - 2024

Last day of trading with warrants of series TO4 in Toleranzia is today, 17 October 2024

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA,...

16 October - 2024

Toleranzia brings forward the publication of the Q3 report for 2024

Toleranzia AB (the ”Company" or "Toleranzia") brings forward the publication of the interim report for the...

7 October - 2024

The exercise period for Toleranzia’s warrants of series TO4 begins today

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA,...

2 October - 2024

Toleranzia submits a clinical trial application (CTA) for the drug candidate TOL2 for the treatment of myasthenia gravis

Toleranzia AB (the ”Company" or "Toleranzia") today announces that it has filed a CTA with the...

28 August - 2024

Toleranzia has received subscription commitments regarding the exercise of warrants of series TO4 corresponding to approximately 71.14 percent

Toleranzia AB (the ”Company" or "Toleranzia") has entered into subscription commitments with Flerie Invest AB, Zonda...

23 August - 2024

Toleranzia AB: Interim report second quarter 2024

Three months, April 1 – June 30 Operating profit/loss amounted to KSEK -1 788 (-2 490)...

2 August - 2024

Toleranzia AB contracts clinical CRO for the phase I/IIa study of TOL2

Toleranzia AB ("Toleranzia" or the "Company") hereby announces that the Company today entered into an agreement...

26 July - 2024

Toleranzia AB appoints Ann-Sofie Taube as CFO of the company on an interim basis

Toleranzia AB ("Toleranzia") hereby announces that the company has appointed Ann-Sofie Taube as CFO on an...

19 June - 2024

Announcement from the 2024 Annual General Meeting of Toleranzia AB (publ)

The Annual General Meeting of Toleranzia AB (publ), 556877-2866, (the "Company") took place today, 19 June...

31 May - 2024

Toleranzia AB conducts successful safety study of TOL2 in blood samples from patients with myasthenia gravis

Toleranzia previously reported the successful completion of a GLP-toxicology study of TOL2, a regulatory milestone for...

20 May - 2024

Notice of Annual General Meeting in Toleranzia AB (publ)

The shareholders of Toleranzia AB (publ), 556877-2866, ("Toleranzia" or the "Company"), are hereby invited to the...

20 May - 2024

Toleranzia AB: Interim report first quarter 2024

Three months, January 1 – March 31·         Operating profit/loss amounted to KSEK -1,641 (-1,988).·         Cash flow...

30 April - 2024

Toleranzia AB: Annual report for the financial year 2023

Toleranzia AB today publishes its annual report and auditors' report for the financial year 2023. The...

25 April - 2024

Correction: Toleranzia AB receives loan commitment of SEK 20 million

Correction: A MAR label was missing in the press release published on April 24, 2024. Consequently,...

24 April - 2024

Toleranzia AB receives loan commitment of SEK 20 million

Toleranzia AB ("Toleranzia" or the "Company") has today signed an agreement with Flerie Invest AB including...

18 March - 2024

Toleranzia reports positive outcome from advisory meeting with the German Medicines Agency for the TOL2 development program

Toleranzia AB has successfully completed a scientific advisory meeting with the German Medicines Agency, Paul Ehrlich...

23 February - 2024

Toleranzia AB – Year-End Report 2023

Three months, October 1 – December 31·         Operating profit/loss (EBIT) amounted to KSEK -2,121 (-2,181).·         Cash...

15 January - 2024

Toleranzia successfully completes GLP toxicology study of TOL2

Toleranzia AB ("Toleranzia" or the "Company") today announces that the pivotal toxicology study, conducted under Good...

21 December - 2023

Toleranzia AB starts production of finished drug product for clinical studies

Toleranzia AB announces today that the company has entered into an agreement with the contract manufacturer...

15 December - 2023

Toleranzia AB presents Nomination Committee

Toleranzia AB (publ) publishes the Nomination Committee’s composition for the Annual General Meeting in 2024. The...

6 December - 2023

Toleranzia reports positive feedback from meeting with the Danish Medicines Agency

Toleranzia AB has successfully completed a scientific advisory meeting with the Danish Medicines Agency, DKMA, on...

27 October - 2023

Toleranzia AB: Interim report third quarter 2023

Three months, July 1 – September 30·         Net sales amounted to — KSEK (–)·         Profit after...

16 October - 2023

Toleranzia appoints Thomas Pålsson as new Chief Financial Officer

Toleranzia AB ("Toleranzia" or the "Company") announces today that Thomas Pålsson has been appointed as new...

26 September - 2023

Toleranzia starts toxicology study of its lead drug candidate TOL2

Toleranzia AB ("Toleranzia" or the "Company") today announces that it has started the regulatory GLP-toxicology study...

15 September - 2023

Toleranzia announces outcome in rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR...

28 August - 2023

Toleranzia publishes prospectus in connection with rights issue of units

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR...

25 August - 2023

Toleranzia AB: Interim report second quarter 2023

Three months, April 1 – June 30·         Net sales amounted to — KSEK (–)·         Profit after...

24 August - 2023

Toleranzia establishes a freeze-dried formulation of the TOL2 drug product

Toleranzia AB ("Toleranzia" or the "Company") today announces that it has finalized the development of an...

21 August - 2023

Toleranzia runs GMP manufacturing of drug candidate TOL2 for clinical study

Toleranzia AB ("Toleranzia" or the "Company") today announces that it has successfully completed the manufacturing steps...

18 August - 2023

Toleranzia carries out a rights issue of units of approximately SEK 55 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE...

7 June - 2023

Announcement from the 2023 Annual General Meeting of Toleranzia AB (publ)

The Annual General Meeting of Toleranzia AB (publ), 556877-2866, (the "Company") took place today, 7 June...

9 May - 2023

Notice of Annual General Meeting of Toleranzia AB (publ)

The shareholders of Toleranzia AB (publ), 556877-2866, ("Toleranzia" or the "Company"), are hereby invited to attend...

3 May - 2023

Toleranzia AB: Interim report 2023-01-01 – 2023-03-31

First quarter, 2023 Three months, January 1 – March 31·         Net sales amounted to — KSEK...

6 April - 2023

Toleranzia AB publishes annual report for the financial year 2022

Toleranzia AB today publishes its annual report and auditors' report for the financial year 2022. The...

31 March - 2023

Toleranzia receives funding from Vinnova for ANCA vasculitis project

Toleranzia AB ("Toleranzia" or the "Company") announces today that the Company has been awarded a grant...

30 March - 2023

Toleranzia concludes manufacturing of a technical batch of drug candidate TOL2

Toleranzia AB ("Toleranzia" or the "Company") today announces that it has successfully manufactured a technical batch...

29 March - 2023

Toleranzia files patent application for tolerogen combination treatments

Toleranzia AB ("Toleranzia" or the "Company") today announces that it has filed a new patent application...

24 February - 2023

Toleranzia AB – Year-End Report 2022

Fourth quarter 2022Fourth quarter, 1 October – 31 December·         Net sales amounted to — KSEK (–)·        ...

12 January - 2023

Toleranzia AB presents Nomination Committee

Toleranzia AB (publ) publishes the Nomination Committee’s composition for the Annual General Meeting in 2023. The...

27 December - 2022

Toleranzia selects Charles River Laboratories for the GLP toxicology study of its drug candidate TOL2

Toleranzia AB (publ) today announces that it has entered into an agreement with Charles River Laboratories...

1 December - 2022

Toleranzia announces successful large-scale production of drug candidate TOL2

Toleranzia AB ("Toleranzia" or the "Company") today announces that it has successfully manufactured and evaluated a...

28 November - 2022

Statement from the Board of Directors of Toleranzia AB regarding Flerie Invest’s mandatory bid

The Board of Directors of Toleranzia AB (publ) ("Toleranzia" or the "Company") recommends that the shareholders...

14 November - 2022

Flerie Invest AB has announced a mandatory bid to the shareholders of Toleranzia AB

Flerie Invest AB ("Flerie Invest") announced on 2 November 2022 that Flerie Invest has increased its...

28 October - 2022

Toleranzia AB: Interim report 2022-01-01 – 2022-09-30

Third quarter 2022 Third quarter, 1 July – 30 September·         Net sales amounted to — KSEK...

26 August - 2022

Toleranzia AB: Interim report 2022-01-01 – 2022-06-30

Second quarter 2022 Second quarter, 1 April – 30 June·         Net sales 0 SEK (0 SEK).·        ...

15 August - 2022

Toleranzia appoints Torbjörn Sannerstedt as new Chief Financial Officer

Toleranzia AB (publ) ("Toleranzia" or the "Company") today announces that the Company has appointed Torbjörn Sannerstedt...

3 June - 2022

Announcement from the 2022 Annual General Meeting of Toleranzia AB (publ)

The Annual General Meeting of Toleranzia AB (publ), 556877-2866, (the "Company") took place today, 3 June...

3 June - 2022

Positive results for Toleranzia’s drug candidate TOL2 published in reputable scientific journal

Toleranzia AB (publ) ("Toleranzia" or the "Company") today announces that the results of preclinical studies with...

10 May - 2022

Toleranzia attends international scientific conference on myasthenia gravis in the USA

Toleranzia AB (publ) ("Toleranzia" or the "Company") today announces that it will participate in The 14th...

9 May - 2022

Toleranzia takes part in a research consortium that has been granted support from the Swedish Knowledge Foundation

Toleranzia AB (publ) ("Toleranzia" or the "Company") today announces that the Swedish Knowledge Foundation, KKS, has...

6 May - 2022

Toleranzia AB: Interim Report 2022-01-01 – 2022-03-31

First quarter 2022 First quarter, 1 January – 31 March·         Net sales 0 SEK (0 SEK).·        ...

4 May - 2022

Notice of Annual General Meeting of Toleranzia AB (publ)

The shareholders of Toleranzia AB (publ), 556877-2866, ("Toleranzia" or the "Company"), are hereby invited to attend...

6 April - 2022

Toleranzia AB publishes annual report for the financial year 2021

Toleranzia AB today publishes its annual report and auditors' report for the financial year 2021. The...

28 March - 2022

Toleranzia secures access to materials for large-scale manufacturing of drug candidate TOL2

Toleranzia AB (publ) ("Toleranzia" or the "Company") today announces that the Company has taken additional steps...

11 November - 2021

Start of Toleranzia’s planned clinical trial with TOL2 postponed due to global shortage of certain materials for production of the drug substance

Toleranzia AB (publ) today announces that the planned start of a first clinical study of its...

10 November - 2021

Toleranzia appoints Ann-Charlotte Rosendahl as Chair of the Board

Toleranzia AB (publ) today announces that its Board of Directors has appointed Ann-Charlotte Rosendahl as new...

21 September - 2021

Toleranzia AB (publ): Receives approximately SEK 42 million through fully subscribed directed share issue

Toleranzia AB (publ) (”Toleranzia” or the ”Company”) today announces the outcome of the directed share issue...

20 September - 2021

Approximately 95.7 per cent of the warrants of series TO3 were subscribed and Toleranzia AB will receive approximately MSEK 27.5

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR...

16 September - 2021

Bulletin from the extraordinary general meeting in Toleranzia AB (publ) on 16 September 2021

The extra general meeting in Toleranzia AB (publ), reg. no. 556877-2866 (”Toleranzia” or ”the Company”), was...

13 September - 2021

The last day for trading in the warrants of series TO3 in Toleranzia AB (publ) is today, 13 September 2021

Today, 13 September 2021, is the last day for trading in warrants of series TO3 in...

30 August - 2021

The subscription price for the use of warrants of series TO3 in Toleranzia AB has been set at SEK 1.14 and the subscription period will start on 1 September 2021

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR...

24 August - 2021

Toleranzia announces continued promising results in the production of TOL2

Toleranzia AB ("Toleranzia" or the "Company") has conducted so called “consistency batches” at the contract manufacturer...

10 August - 2021

Notice of extraordinary general meeting of Toleranzia AB (publ)

The shareholders of Toleranzia AB (publ), org.nr 556877-2866 ("Toleranzia" or the "Company"), are hereby convened to...

9 August - 2021

Toleranzia AB (publ): The board of directors proposes extraordinary general meeting to resolve on a directed share issue of up to circa SEK 42 million and to elect a new board member

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR...